Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aptose Biosciences

1.71
+0.0000
Volume:- -
Turnover:- -
Market Cap:4.36M
PE:-0.05
High:1.71
Open:1.71
Low:1.71
Close:1.71
Loading ...

Aptose Biosciences' Shares Tumble Ahead of Nasdaq Delisting

Dow Jones
·
02 Apr

Nasdaq Surges 1%; US Construction Spending Rises In February

Benzinga
·
02 Apr

Aptose Biosciences Says Shares to Be Delisted From Nasdaq

MT Newswires Live
·
01 Apr

Aptose Biosciences shares to delist from Nasdaq as of April 2

TIPRANKS
·
01 Apr

Aptose Biosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
29 Mar

Aptose Biosciences: Promising Clinical Progress and Strategic Collaborations Justify Buy Rating

TIPRANKS
·
29 Mar

Press Release: Aptose Reports Year End 2024 Results and Corporate Highlights

Dow Jones
·
28 Mar

Aptose Biosciences Inc expected to post a loss of $10.50 a share - Earnings Preview

Reuters
·
22 Mar

Aptose Biosciences Regains Compliance With Nasdaq's Minimum Bid Price Requirement

MT Newswires Live
·
17 Mar

Aptose Biosciences meets Nasdaq minimum bid price compliance

TIPRANKS
·
17 Mar

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

GlobeNewswire
·
17 Mar

Aptose Biosciences Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Price Target $12.5

THOMSON REUTERS
·
27 Feb

Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

GlobeNewswire
·
20 Feb

Aptose Announces Reverse Share Split

GlobeNewswire
·
19 Feb

Aptose Biosciences Inc Files Prospectus Related To Resale Of Up To 12 Million Common Shares By Selling Stockholders- SEC Filing

Reuters
·
14 Feb

Aptose Biosciences files to sell 12.03M shares of common stock for holders

TIPRANKS
·
14 Feb

Aptose Biosciences Establishes $25M Equity Facility

TIPRANKS
·
14 Feb

Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility

GlobeNewswire
·
14 Feb

Aptose Biosciences Price Target Maintained With a $2.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Feb

Promising Results from Aptose Biosciences’ TUSCANY Trial Boost Joseph Pantginis’ Buy Rating

TIPRANKS
·
12 Feb